Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.62%77 Cyclically Adjusted Price-to-FCF is 23.89 as of Aug. 04, 2026, which is 56% below its 10-year median of 53.90. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 266 Medical Devices & Instruments companies, Coloplast AS ranks better than 61.28% on this metric.
The historical rank and industry rank for Coloplast AS's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
CLPBY'
s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 20.97 Med: 53.9 Max: 86.54
Current: 22.35
During the past years, Coloplast AS's highest Cyclically Adjusted Price-to-FCF was 86.54. The lowest was 20.97. And the median was 53.90.
CLPBY's Cyclically Adjusted Price-to-FCF is ranked better than 61.28% of 266
companies
in the Medical Devices & Instruments industry
Industry Median: 31.07
vs CLPBY: 22.35
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Coloplast AS's adjusted free cash flow per share data for the three months ended in Mar. 2026 was $0.070. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.28 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Coloplast AS (OTCPK:CLPBY) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Coloplast AS Cyclically Adjusted Price-to-FCF Related Terms
Coloplast AS Cyclically Adjusted Price-to-FCF Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS Cyclically Adjusted Price-to-FCF Chart
CLPBY vs ISRG, BDX, MDLN: Cyclically Adjusted Price-to-FCF Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Cyclically Adjusted Price-to-FCF falls into.
Coloplast AS Cyclically Adjusted Price-to-FCF Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Coloplast AS's Cyclically Adjusted Price-to-FCF for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted Price-to-FCF of 23.89 mean?
Coloplast AS (CLPBY) has a Cyclically Adjusted Price-to-FCF of 23.89 as of Aug. 04, 2026. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Coloplast AS and its competitors. This is 56% below median its historical median of 53.90. Over the past decade, Coloplast AS's Cyclically Adjusted Price-to-FCF has ranged from 20.97 to 86.54. According to the industry distribution chart, Coloplast AS ranks #103 out of 266 companies in the Medical Devices & Instruments industry, placing it in the top 38.7%.
Is Coloplast AS's Cyclically Adjusted Price-to-FCF too high?
Coloplast AS's current Cyclically Adjusted Price-to-FCF of 23.89 is 56% below median its 10-year median of 53.90. Over the past 10 years, this metric has ranged from a low of 20.97 to a high of 86.54. The Medical Devices & Instruments industry median Cyclically Adjusted Price-to-FCF is 31.07. Coloplast AS's value of 23.89 is 23.1% below this industry median. Based on the distribution chart, Coloplast AS ranks #103 out of 266 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Cyclically Adjusted Price-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #103 out of 266 companies for Cyclically Adjusted Price-to-FCF. This puts Coloplast AS in the upper half of its industry. The industry median Cyclically Adjusted Price-to-FCF is 31.07. Coloplast AS's value of 23.89 is 23.1% below this benchmark. Historically, Coloplast AS's own Cyclically Adjusted Price-to-FCF has ranged from 20.97 to 86.54 over the past decade. While the company's 10-year median is 53.90 vs. the industry median of 31.07, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Price-to-FCF for a Medical Devices & Instruments company?
The median Cyclically Adjusted Price-to-FCF among Medical Devices & Instruments companies is 31.07, based on 266 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted Price-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted Price-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Cyclically Adjusted Price-to-FCF of 23.89 is 23.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Price-to-FCF mean?
A high Cyclically Adjusted Price-to-FCF can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted Price-to-FCF Ratio is the ratio of share price to a company's inflation-adjusted FCF per share over a 10-year period. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted Price-to-FCF is 31.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Cyclically Adjusted Price-to-FCF is 23.89, which is 56% below median its own 10-year median of 53.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.69 — trading 48.7% below its estimated fair value. The current Cyclically Adjusted Price-to-FCF is 23.89, which is 56% below median its 10-year median of 53.90 and 23.1% below the Medical Devices & Instruments industry median of 31.07. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Price-to-FCF calculated?
Cyclically Adjusted Price-to-FCF is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Cyclically Adjusted Price-to-FCF is 23.89 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.69 is trading 48.7% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Cyclically Adjusted Price-to-FCF: 23.89 (56% below median its 10-year median of 53.90)
GF Value™: $13.05 vs. price of $6.69 (48.7% below fair value)
Industry Position: 23.1% below the Medical Devices & Instruments median (#103 of 266)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Cyclically Adjusted Price-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
